Literature DB >> 29736870

Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM).

Sümeyye Merve Türk1, Döndü Üsküdar Cansu2, Hava Üsküdar Teke3, Timuçin Kaşifoğlu4, O Meltem Akay5, Muzaffer Bilgin6, Cengiz Korkmaz4.   

Abstract

The higher incidence of arterial and venous events is well established in patients with rheumatoid arthritis (RA). Our aim here was to investigate whether there is a prothrombotic state in RA patients by using rotational thromboelastometry (ROTEM) method and to demonstrate whether the disease variables play a role in this process. A total of 85 patients who met the 2010 RA classification criteria were consecutively included in the study. The patients with RA who have been using antiaggregant, anticoagulant, or nonsteroidal anti-inflammatory drugs (NSAIDs) and had a history of arterial or venous thromboembolism were excluded from the study. Their complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, D-dimer, and lipid profiles were measured, DAS-28 disease activation scores were calculated, and simultaneous ROTEM analysis was performed to determine the predisposition to thrombosis. Of the ROTEM parameters, clotting time (CT, seconds (s)), clot formation time (CFT, s), and maximum clot firmness (MCF) were evaluated. Having a shorter CT and/or CFT in intrinsic (I) or extrinsic (E) pathway and/or a longer MCF compared to the healthy controls was considered as "predisposition to hypercoagulability". The mean age of the 85 RA patients were 54.12 ± 13 years, and 77.6% of the patients were female (n = 66). Of the patients, 52.9% (n = 45) were using methotrexate (MTX) ± hydroxychloroquine (HCQ) ± corticosteroid (CS), while 43.5% (n = 37) were using anti-tumor necrosis factor (TNF) ± MTX. Active steroid usage was ongoing in 64.7% of the patients (n = 55). When evaluated according to DAS-28, in those with higher disease activity, a shorter I-CFT and greater I-MCF were determined (p = 0.020 and p = 0.033, respectively). In those with higher disease activity based on the correlation analysis, I-CFT and E-CFT were shorter and I-MCF and E-MCF were longer, indicating a higher predisposition to thrombosis. Using linear regression, variables with a major effect on ROTEM parameters were identified as DAS-28, CRP, and platelet count. As the first study in the literature, we identified that disease activation is the most important risk factor for prothrombotic state in RA patients irrespective of the drugs used. ROTEM can be used in clinical practice to predict thrombotic events in RA patients.

Entities:  

Keywords:  Rheumatoid arthritis; Rotational thromboelastography; Thromboelastography; Thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29736870     DOI: 10.1007/s10067-018-4134-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

Review 1.  Inflammation-induced thrombosis: mechanisms, disease associations and management.

Authors:  Kenan Aksu; Ayhan Donmez; Gokhan Keser
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.

Authors:  Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

Review 3.  C-reactive protein and venous thromboembolism: causal or casual association?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Martina Montagnana; Massimo Franchini
Journal:  Clin Chem Lab Med       Date:  2010-08-13       Impact factor: 3.694

4.  Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations.

Authors:  Kimberly P Liang; Kelly V Liang; Eric L Matteson; Robyn L McClelland; Teresa J H Christianson; Carl Turesson
Journal:  Arthritis Rheum       Date:  2006-02

5.  Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.

Authors:  S Wållberg-Jonsson; H Johansson; M L Ohman; S Rantapää-Dahlqvist
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

6.  Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system.

Authors:  I A M van den Oever; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

Review 7.  The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

Authors:  D J Wallace; M Linker-Israeli; A L Metzger; V J Stecher
Journal:  Lupus       Date:  1993-02       Impact factor: 2.911

8.  Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study.

Authors:  Wei-Sheng Chung; Chiao-Ling Peng; Cheng-Li Lin; Yen-Jung Chang; Yung-Fu Chen; John Y Chiang; Fung-Chang Sung; Chia-Hung Kao
Journal:  Ann Rheum Dis       Date:  2013-08-07       Impact factor: 19.103

9.  Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis.

Authors:  K-J Kim; I-W Baek; K-S Park; W-U Kim; C-S Cho
Journal:  Lupus       Date:  2016-08-09       Impact factor: 2.911

10.  Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  Rebecca Davies; James B Galloway; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2011-07-22       Impact factor: 19.103

View more
  7 in total

1.  Evaluating hypercoagulability in new-onset systemic lupus erythematosus patients using thromboelastography.

Authors:  Huiyun Gong; Ce Shi; Zhuochao Zhou; Jialin Teng; Yue Sun; Chengde Yang; Xuefeng Wang; Junna Ye
Journal:  J Clin Lab Anal       Date:  2019-12-16       Impact factor: 2.352

Review 2.  Oxidative Stress in Rheumatoid Arthritis: What the Future Might Hold regarding Novel Biomarkers and Add-On Therapies.

Authors:  Lucas José Sá da Fonseca; Valéria Nunes-Souza; Marília Oliveira Fonseca Goulart; Luiza Antas Rabelo
Journal:  Oxid Med Cell Longev       Date:  2019-12-14       Impact factor: 6.543

3.  Accelerated Spatial Fibrin Growth and Impaired Contraction of Blood Clots in Patients with Rheumatoid Arthritis.

Authors:  Alina D Peshkova; Tatiana A Evdokimova; Timur B Sibgatullin; Fazoil I Ataullakhanov; Rustem I Litvinov; John W Weisel
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

4.  Detection of Citrullinated Fibrin in Plasma Clots of Rheumatoid Arthritis Patients and Its Relation to Altered Structural Clot Properties, Disease-Related Inflammation and Prothrombotic Tendency.

Authors:  Johannes A Bezuidenhout; Chantelle Venter; Timothy J Roberts; Gareth Tarr; Douglas B Kell; Etheresia Pretorius
Journal:  Front Immunol       Date:  2020-12-04       Impact factor: 7.561

5.  The Efficacy of Antioxidative Stress Therapy on Oxidative Stress Levels in Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Liuting Zeng; Ganpeng Yu; Kailin Yang; Jun Li; Wensa Hao; Hua Chen
Journal:  Oxid Med Cell Longev       Date:  2021-10-07       Impact factor: 6.543

Review 6.  The Effect of TNF-α on CHD and the Relationship between TNF-α Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review.

Authors:  Yezhou Qian; Menghui Mao; Feige Nian
Journal:  Cardiol Res Pract       Date:  2022-08-24       Impact factor: 1.990

Review 7.  Evaluation of the Risk of Getting Peripheral Artery Disease in Rheumatoid Arthritis and the Selection of Appropriate Diagnostic Methods.

Authors:  Surik Sedrakyan; Tehreem Fatima; Mst Khaleda Khatun; Muhammad R Awan; Nkechi A Okam; Nusrat Jahan
Journal:  Cureus       Date:  2020-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.